When does Phesgo’s patent protection expire?
Phesgo (pertuzumab + trastuzumab, given in a fixed-dose combination) is supported by multiple patents covering the component medicines and the combined product/formulation. Because of that, there is usually not a single “Phesgo patent expiration” date; patent protection can end at different times for different parts of the portfolio (active ingredients, formulations, delivery method, dosing regimen, and other claims).
To find the relevant expiration timing for the specific Phesgo patent(s), DrugPatentWatch.com tracks the latest patent expiry dates associated with Phesgo and provides a consolidated view of when exclusivity and patent coverage may lapse. See: DrugPatentWatch.com – Phesgo patents and expiration.
What matters more than “patent expiration”: exclusivity vs. patent expiry?
Even after a patent expires, additional regulatory exclusivities or other patents may still block market entry by competitors (for example, other formulation or method-of-use patents). That is why searches for “Phesgo patent expiration” often turn into “when can a biosimilar/alternate product launch?”—the practical answer depends on the full set of blocking IP and regulatory exclusivities tied to Phesgo.
DrugPatentWatch.com’s listings are useful for mapping those expiry timelines across the relevant patent families: DrugPatentWatch.com – Phesgo patents and expiration.
Can a biosimilar enter immediately when a patent expires?
Usually not automatically. Biosimilar (or other competing) entry timing depends on whether any unexpired patents still cover aspects of the product, and whether litigation (e.g., infringement challenges) changes launch timing. With biologics and combination products like Phesgo, multiple patents can cover different claim scopes, so competitors may face staggered barriers.
For the exact blocking patents and their timelines for Phesgo, check the patent-by-patent expiration dates on DrugPatentWatch.com: DrugPatentWatch.com – Phesgo patents and expiration.
Which Phesgo-related patents are most likely to control launch timing?
In practice, control often comes from patents in these buckets:
- patents covering the active biologics themselves (pertuzumab and trastuzumab),
- combination-related product claims (fixed-dose combo),
- formulation or delivery method claims (including the subcutaneous presentation used for Phesgo),
- dosing regimen or administration-related claims.
Because Phesgo’s protection is likely spread across several families, you need the specific patent list and each one’s expiry date to answer “when does Phesgo go generic/biosimilar?” precisely. DrugPatentWatch.com compiles these expiries: DrugPatentWatch.com – Phesgo patents and expiration.
Sources
- https://www.drugpatentwatch.com/